With cancer being the fastest growing healthcare priority in the pharmaceutical industry, IBC Asia announces the region's first ever strategic oncology conference focusing on clinical development and market access. Download the brochure now to identify new trends and opportunities in development and commercialization in the region. ONCOLOGY ASIA focuses on the clinical development and effective market access for cancer drugs in Asia. It will cover strategies for developing oncology products and businesses from innovative pipelines, commercializing products, sales and marketing strategies to capture opportunities in Asia’s markets. Featured sessions from top industry thought leaders: Market Trends and Drivers in the Region • James Garner, Head Unit Development Operations, Asia R&D, Sanofi, Singapore What You Need to Know When Marketing Oncology Drugs • Dr Paul Cornes, Clinical Oncologist, Bristol Oncology Centre, UK Successful Market Access Strategies for Oncology Drugs • Sameer Agarwal, Senior Vice President, Business Center Strategic Marketing, Fresenius Kabi Deutschland GmbH, Germany Clinical Engagement for Successful Oncology Products • Dr Anish Desai, Director Medical & Clinical Affairs, Johnson & Johnson, India http://www.oncologyasia.com
6
Life Sciences IBC LIFE SCIENCES www.oncologyasia.com Produced by: International Marketing Partner: Media Partners: Asia’s only strategic oncology conference focusing on clinical development and market access ASIA Expediting Development and Improving Market Access Hear from Industry Leaders on Timely Topics Including: Market Trends and Drivers in the Region James Garner Head Unit Development Operations Asia R&D Sanofi, Singapore What You Need to Know When Marketing Oncology Drugs Dr Paul Cornes Clinical Oncologist Bristol Oncology Centre United Kingdom mABs and Biosimilars in Oncology Li-Chung Huang Chief Quality Officer Henlius Biopharmaceuticals USA/China Developing Competitive Pipelines & New Collaborative Research Models Jin-San Yoo President and CEO PharmAbcine, Korea Successful Market Access Strategies for Oncology Drugs Sameer Agarwal Senior Vice President, Business Center Strategic Marketing Fresenius Kabi Deutschland GmbH Germany Clinical Engagement for Successful Oncology Products Dr Anish Desai Director Medical & Clinical Affairs Johnson & Johnson, India Pre-Conference Workshop 25 November 2014 Oncology Clinical Trials Post-Conference Workshop 28 November 2014 Pricing and Reimbursement Models for Oncology Products mAbs and Biosimilars A B C Oncology Clinical Trials in Asia Prof Alex Matter CEO Experimental Therapeutics Centre, A*Star Singapore 25 - 28 November 2014 | PARKROYAL on Beach Road, Singapore
Transcript
LifeSciences
IBCLIFE SCIENCES
www.oncologyasia.com
Produced by: International Marketing Partner:Media Partners:
Asia’s only strategic oncology conference focusing onclinical development and market access
ASIAExpediting Development and Improving Market Access
Hear from Industry Leaders on Timely Topics Including:
Market Trends and Driversin the RegionJames GarnerHead Unit Development Operations Asia R&DSanofi, Singapore
What You Need to Know WhenMarketing Oncology DrugsDr Paul CornesClinical OncologistBristol Oncology CentreUnited Kingdom
mABs and Biosimilars inOncologyLi-Chung HuangChief Quality OfficerHenlius Biopharmaceuticals USA/China
Developing CompetitivePipelines & New CollaborativeResearch ModelsJin-San YooPresident and CEOPharmAbcine, Korea
Successful Market AccessStrategies for Oncology DrugsSameer AgarwalSenior Vice President,Business Center Strategic MarketingFresenius Kabi Deutschland GmbH Germany
Clinical Engagement forSuccessful Oncology ProductsDr Anish DesaiDirector Medical & Clinical AffairsJohnson & Johnson, India
Pre-Conference Workshop25 November 2014
Oncology Clinical Trials
Post-Conference Workshop28 November 2014
Pricing and ReimbursementModels for Oncology Products
mAbs and Biosimilars
A
B
C
Oncology Clinical Trialsin AsiaProf Alex MatterCEOExperimental Therapeutics Centre, A*StarSingapore
25 - 28 November 2014 | PARKROYAL on Beach Road, Singapore
Dr Paul Cornes, Clinical Oncologist, Bristol Oncology Centre,United Kindgom
TRENDS AND MARKET OVERVIEW
9:10 Market Trends and Drivers in the Region
• Outlook and opportunities for regional and global players• The evolving landscape of the industry• Demographics and healthcare trends in the region• Market share, segmentation, oncology main players and
new playersJames Garner, Head Unit Development Operations, Asia R&D,Sanofi, Singapore
9:50 Developing Competitive Pipelines, Drug Discovery
Platforms and New Collaborative Research Models
• Expanding global business opportunities throughcollaboration
• Updates on progress of recent licensing deal• Evaluating the best time to partner or outsource• Choosing the right company to partner with to support
business strategyJin-San Yoo, President and CEO, PharmAbcine, Korea
10:30 Morning Networking and Refreshment Break
NEXT GENERATION ONCOLOGYPRODUCTS
11:00 mABs and Biosimilars in Oncology
• Current status of biosimilar development in oncology• Effective monoclonal antibody development program in
oncology• Lessons learned in quality, compliance and regulatory
approvals• Key successful factors in developing and marketing
biosimilars in oncologyLi-Chung Huang, Chief Quality Officer, Henlius
Biopharmaceuticals, USA/China
11:40 Addressing the Oncology NCE Bottleneck
• Taking an oncology drug from bench to clinical• Less is More: Regulatory strategy of a liver cancer drug• How the right drug delivery system can help• Development strategy with global business opportunityDr Yunlong Tseng, Vice President, TLC Bio, Taiwan
12:20 Networking Lunch
13:30 Roundtable Discussions:
• Clinical Development
Melvin Toh, Vice President Pharmaceutical Development,CK Life Sciences, Hong Kong
• Early R&D
Dr Paul Cornes, Consultant Clinical Oncologist,Bristol Oncology Centre
• Our expectations from the pharma industry• How we prefer to be engaged• Our biggest challenge when interfacing with pharma
representatives• Advice to the industryProf Roel Tolentino, Immediate Past President,Philippine Society of Oncology
9:50 What You Need to Know When Marketing Oncology Drugs
• Facing the reality of corruption in medicine• Impact of corruption on even the most ethical pharma
company• How does a company work with the expectation of bribes
and extortion?• Options and alternativesDr Paul Cornes, Consultant Clinical Oncologist,Bristol Oncology Centre, United Kingdom
10:30 Morning Networking and Refreshment Break
11:00 Clinical Engagement for Successful Oncology Products
• Addressing the user concern on safety and driving changein prescriptions
• Effectively engaging stakeholders to communicateproduct value
• Publications, trainings and seminars to further educateclinicians
• Lessons learned from the regionDr Anish Desai, Director Medical & Clinical Affairs,Johnson & Johnson, India
MARKET ACCESS
11:40 Successful Market Access Strategies for Oncology Drugs
• Drivers of success for the oncology business• Understanding the impact of changing healthcare markets
on oncology products• Market dynamics and strategies to suitably address the
challenges• Key criteria to consider for success in marketingSameer Agarwal, Senior Vice President, Business CenterStrategic Marketing, Fresenius Kabi Deutschland GmbH,Germany
12:20 Networking Lunch
14:00 Role of Companion Diagnostics in Oncology
Market Access
• Impact of companion diagnostics in the marketing ofoncology drugs
• Current challenges in development• Driving the marketing of the products• Health economics and patient selectionDr Bhuwnesh Agrawal, Chief Medical Officer,Vela Diagnostics, Singapore
14:40 Preparing to Launch Oncology Drugs
• Growth trends in the region• Early introduction into market• Effective marketing strategies• Do’s and dont’s when launchingKok Leong Chan, Product Manager, Cancer Care Unit (CCU),Roche, Malaysia
15:20 Afternoon Networking and Refreshment Break
15:50 What Works in Asia: Successfully Bringing Oncology
Drugs to Market
• What makes the region different• Impact of demographics and culture in successful business• Key factors to consider when choosing distribution
channels• Final word on successful marketingVikram Shetty, Regional Medical Adviser, Takeda, Singapore
PRICING AND REIMBURSEMENT
16:30 Pricing and Reimbursement Models for Oncology
Products
• Pricing strategies in emerging markets• Lessons learned from established markets• Global challenges and strategies to address theseDr Aamir Shaikh, Founder, Assansa, India
Challenges in cancer treatmentCurrent status of biosimilar development in oncology
Oncology Clinical Trials
mAbs and Biosimilars
This workshop presents strategies and case studies of innovativeapproaches, to help you understand what works and doesn’t workin shortening drug development & regulatory timelines to makenew cancer drugs available to Asian patients faster.
Hear about:Regulatory strategies, e.g. Pre-IND consultation, Fast Track, PriorityReview, Accelerated Approval, Special Review (SFDA)
About Your Workshop Leaders:Melvin Toh, Vice President Pharmaceutical Development, CK Life Sciences
Dr Paul Cornes, Consultant Clinical Oncologist, Bristol Oncology Centre, UK
About Your Workshop Leader:
Li-Chung Huang, Chief Quality Officer, Henlius Biopharmacuetical, USA/ChinaMr. Huang is an executive with 20 years of experience in biotech industry. He was previously worked with Bayer, Centocor, Imclone and Chempartner.He previously served as the Chair of Philadelphia Section for the American Society for Quality (ASQ) and the Chair of Mid-Atlantic Biomedical andPharmaceutical Discussion Group. Throughout a career in biotech industry from scientist/engineer to executive in diverse fields of development,analytical support, tech transfer, validation, manufacturing, quality control, compliance and supply chain, he has been recognized for the ability
to build and lead cross-functional teams and was awarded ten plus awards from the biotech industry and quality community.
Dr. Toh is Vice President, Pharmaceutical Development, at CK Life Sciences. CK Life Sciences pharmaceutical operations include Polynoma (US),Wex Pharmaceuticals (Canada) and Renascence Therapeutics (Hong Kong).
Dr. Toh has a medical degree from the National University of Singapore and a MSc degree from the University of London. He has held variousmanagement/ scientific positions in Asia and the USA, including Director of Clinical Pharmacology in Oncology Development at Pfizer Global R&D
based in San Diego, where he headed a team of scientists working on the clinical development of new cancer drugs. He was also previously Head/MedicalDirector of the Pfizer Clinical Research Unit at the Singapore General Hospital.
Pre-Conference Workshop A 25 November 2014 9:00am - 4:30pm
Post-Conference Workshop B 28 November 2014 9:00 am - 12:00 noon
Pricing and Reimbursement Models for Oncology Products
Post-Conference Workshop C 28 November 2014 1:30 pm - 4:30 pm
This workshop will discuss patients' perspectives of their willingnessto pay for oncology drugs, the search for novel reimbursementmodels, and pricing strategies in emerging markets
Outline:Review papers on willingness to pay for better care in Japan andKoreaSolutions to impending cost-crisis
Led by:Dr Paul Cornes, Consultant Clinical Oncologist, Bristol Oncology Centre, UK
Comparative effectiveness researchA look at key markets in and around the region:• India plans a network of taxpayer funded centres based on
generics/biosimilars only• Korea has highest co-pays in OECD developed nations• US - social support to increase access• UK - pay for success deals• China - across the board demands for a price reduction
Paul has been a NHS cancer clinical trial lead and has lectured on the biennial London TPI course on clinical trial designs and on improving theeffectiveness of clinical trials. He is part of the Wolfson Institute Cochrane Group at Bath and the Clinical Outcomes Group.
Aside from being a NHS cancer clinical trial lead and lecturer on clinical trial designs and on improving the effectiveness of clinical trials, Paulhelped to organise the Cambridge Blue-Sky Future Cancer meeting with the Centre for the Study of Financial Innovation. He encourages physiciansthat health economics is to be embraced as part of routine medical practice. He was involved in the United Kingdom Health Technology Assessmentof Erythropoietins for cancer at NICE and has taught clinical and cost effective care to physicians, pharmacists and nurses in the European Union,in the USA, in the Middle East, Asia and Russia.
Developing cost-effective R&D programs for cancer therapeuticsby adopting new technology and Lean Six SigmaBalancing pre-clinical studies and clinical studiesSuccessful marketing of biosimilars and biobetters in oncology
The impact of study design; innovative oncology trial designs anddevelopment strategies, e.g. adaptive trials, use of biomarkers &surrogate endpoints in oncology clinical trialsThe promise of Asia to support more early phase oncology trialsThe challenges of patient enrolment in oncology trials; Workingwith service providers to improve patient recruitment in oncologyclinical trialsOperational strategies to overcome practical challenges inoncology trials in AsiaThe latest partnership models between sponsors and CROs foroncology trials
IBCLIFE SCIENCES Asia’s only strategic oncology conference focusing on
clinical development and market access
ASIA25 - 28 November 2014 | PARKROYAL on Beach Road, Singapore
Expediting Development and Improving Market Access
Cancer is the fastest growing healthcare priority within the worldwide pharmaceutical industry. The globaloncology market is expected to reach $150B with China’s market alone valued to be about $50 Billion by 2020,growing at a rate of 20% per year.(PharmaAsia October 2013)
The search for ‘the’ cancer blockbuster drug is still on and pharmacompanies still need to create an effective strategy to accessthe market.
Oncology Asia is the first strategy conference that focuseson the development and effective market access of cancerdrugs in the region. This is the meeting to learn how toexpedite oncology clinical development and breakthrough established and emerging markets in Asia.
Why YouShould Attend
Identify new trends and opportunities indevelopment and commercialization in Asia
Learn from in-depth case studies onclinical development and successful market
access for oncology products
Gain insights from industry speakersfrom global and regional
pharma/biotech
BY INDUSTRIES■ Big Pharma 50%
■ CROS 12%
■ Biotechs 10%
■ Medical Device & Diagnostics 5%
■ Generics Companies 5%
■ Research Institutes 5%
■ CRAMS/CMOs 5%
■ Finance / VC 5%
■ Others 3%
BY COUNTRIES■ Singapore 30%
■ Malaysia 10%
■ Rest of SEA 10%
■ Japan 5%
■ Hong Kong 8%
■ China 15%
■ Taiwan 2%
■ USA 10%
■ Rest of the World 10%
Who Should Attend
Raise awareness for your services available to Pharmaceuticalcompanies in Asia.• Do you find difficulty in reaching senior decision makers and
successfully stimulating interest for your services?• Are you trying to raise awareness of the value of your company’s
expertise and services?• Or are you finding it difficult to differentiate your company from
competition?
Perhaps what you need is a branding opportunity at this event!Increase your reach through our extensive marketing campaign,targeted at your qualified business audience.For information about placing your brand & profile top-of-mind tokey buyers, contact Yvonne Leong, Business Development Manageron Tel: + 65 6508 2489 or Email: [email protected]
SPONSORSHIP OPPORTUNITIES
FREEGROUP
DISCOUNT
This label contains your priority booking code. To expedite registration, please do not remove label. If you havealready received a copy of this brochure, we apologise. For reasons of confidentiality, your full particulars were notavailable to IBC Asia (S) Pte Ltd for deduplication prior to mail drop.
Scan the QR Code with yoursmartphone and register today
Customer Service Hotline+65 6508 2401
MAIL the attached registrationform with your cheque toIBC Asia (S) Pte Ltdc/o Informa Regional BusinessServices111 Somerset Road,TripleOne Somerset #10-06,Singapore 238164
Webwww.oncologyasia.com
HOTEL INFORMATION
DATA PROTECTION
PAYMENT TERMS
CANCELLATIONS / SUBSTITUTION
IMPORTANT NOTE
REG
NO. 2
0010
8203
N
Payment must be received 10 business days prior to the event.To take advantage of discounts with an expiry date, registrationand payment must be received by the cut-off date.• Payment by bankers draft or cheque in S$ or US$ should be
made in favour of “IBC Asia (S) Pte Ltd” and mailed to:IBC Asia (S) Pte Ltdc/o Informa Regional Business Services111 Somerset Road, TripleOne Somerset #10-06Singapore 238164Attn: The Accounts Receivable Team
• Payment by bank transfer in S$ or US$ made payable to:IBC Asia (S) Pte LtdA/C No.:147-059513-001 (S$)A/C No.:260-457866-178 (US$)The Hongkong and Shanghai Banking Corporation Limited21 Collyer Quay, HSBC BuildingSingapore 049320Bank Swift Code: HSBCSGSGBank Code: 7232
• Payment by Credit Card (AMEX, VISA or MasterCard).The best way to pay by credit card is through our secureportal built into the website. To pay by phone please indicatethe contact name and details below and our CustomerServices Team will call within 24 hours to take payment.Please do not send credit card information by email.
The personal information entered during your registration/order,or provided by you, will be held on a database and may beshared with companies in the Informa Group in the UK andinternationally. Occasionally, your details may be obtained fromor shared with external companies who wish to communicatewith you offers related to your business activities. If you do notwish your details to be used for this purpose, please contact ourDatabase Department at Email: [email protected],Tel: +65 6508 2400 or Fax: +65 6508 2408.
Should you be unable to attend, a substitute delegate iswelcome at no extra charge. Cancellations must be received inwriting at least 10 business days before the start of the event,to receive a refund less 10% processing fee per registration.The company regrets that no refund will be made available forcancellation notifications received less than 10 business daysbefore the event.
Please quote the name of the delegate, event title and invoicenumber on the advice when remitting payment. Bank chargesare to be deducted from participating organisations own accounts.Please fax your payment details (copy of remittance advice,cheque or draft to +65 6508 2407).Attendance will only be permitted upon receipt of full payment.Participants wishing to register at the door are responsible toensure all details are as published. IBC assumes no furtherliability or obligation, beyond the refund of the paid registrationfee, in the event of postponement or cancellation by IBC.
6 EASY WAYS TO REGISTER
RESERVE YOUR PLACE TODAY!■ Yes! I/We will attend the Oncology Asia, 25 – 28 November 2014, PARKROYAL on Beach Road, Singapore■ I would like to purchase the conference presentations at SGD1000 + GST (SGD1070) per log in.
CREDIT CARD PAYMENTSThe best way to pay by credit card is through our secure on-line registration process, simply log on to the website atwww.oncologyasia.com and click “Register On-line”. If you would prefer to pay over the phone please complete the contact nameand details and our Customer Services Team will call within 24 hours to take payment. As we treat your credit card information in thestrictest confidence, please do not send payment details by email.
Credit card contact: Department:
Direct phone number: Email:
P46255
Who is Head of your Department?Who is Head of Training?
Company InformationCompany Name:
Address:
Main Business/Activity:
Postal Code:
■ I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd■ I am paying by bank transfer (copy attached)■ Payment by Credit Card. (AMEX, VISA or MasterCard accepted)
PAYMENT METHOD(Please tick)
• Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time.Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR special rate OR group rate.
• All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.• A 7% Goods & Services Tax (GST) is applicable to all Singapore based companies for Singapore Venue.
Please photocopy for additional delegates
Early Bird RateRegister & pay on orbefore 12 Sep 2014
Special RateRegister & pay on orbefore 10 Oct 2014
